On paper, biosimilars have great potential to cut development costs, expand patient access to biologics, and improve affordability. The practical reality is that these goals are difficult to achieve.

In the United States, where around 8 million people rely on insulin for diabetes management, soaring prices have created barriers to accessibility. As Congress takes initial steps to cap monthly ...

Neion Bio’s Raptor™ platform utilizes cutting-edge genetic engineering to harness nature’s most efficient molecular factories ...

Pharmacy benefit managers received substantial attention during 2024. Congress and regulating agencies including the FTC and HHS scrutinized PBM business practices and related profits. As a new ...

New drug manufacturer Neion Bio has emerged from stealth after incubating a novel way to cook up biologic drugs. | The new ...

As Novartis’ Sandoz unit prepares to go it alone, the off-patent medicines specialist is buckling up for the biosimilars long haul. Sandoz on Tuesday struck an accord with Just – Evotec Biologics to ...

A biosimilar drug manufacturer is concentrating on process optimization to increase uptake of its products in lower-income countries. According to Jeffrey Hausfeld, MD, chairman of the board of ...

(MENAFN- GlobeNewsWire - Nasdaq) The global biosimilar contract manufacturing market size was valued at USD 9.22 billion in 2025 and is predicted to hit around USD 52.23 billion by 2035, rising at a ...

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help ...

Please provide your email address to receive an email when new articles are posted on . The patents for bevacizumab and ranibizumab expired in 2019 and 2020, respectively, in the U.S. and in 2022 in ...

Providers and patients who want to understand biosimilars can now navigate through a new web app, that was created by Prime, and delivered in partnership with the AMCP Foundation and Biosimilars ...

Large Molecule Drug Substance CDMO Market Report Overview: The large molecule drug substance CDMO market is projected to grow at a CAGR of approximately 9% over the forecast period. This growth is ...